Dutcher J P
Semin Nucl Med. 1984 Jul;14(3):251-61. doi: 10.1016/s0001-2998(84)80018-5.
The use of radioisotopes for cell labeling has been a major tool in hematology laboratory research. Chromium-51-labeling of hematologic cells and lymphocytes has been used for years to study the migration and sequestration of these cells in the spleen and other sites. The substantial recirculation of lymphocytes from blood into lymphoid tissue and back into blood is well described. Recently, new approaches for radiosotopic cell labeling have gained prominence in the investigation of various aspects of malignant diseases and in the clinical care of such patients. Isotopes such as indium-111 can be visualized with standard scanning techniques providing further information about the migration of normal and malignant cells has been discovered. In vivo studies have been performed with indium-111 in animals and humans, including comparisons of the migration of abnormal cells (malignant) and of lymphocytes to abnormal nodes. Evaluation and comparison of the migration of carcinoma cells, normal lymphoid cells, and malignant lymphoid cells in animals show markedly different patterns of distribution, which could have bearing on investigations of mechanisms of metastasis. In vivo human studies also have evaluated the migration patterns of lymphoid cells from patients with chronic lymphocytic leukemia and well-differentiated lymphoma, showing very different migrating behavior between these two polarities of a similar disease. These types of studies, while initially phenomenonologic, may provide a basis for a better understanding of these diseases. There are concerns about the use of an isotope such as indium-111 for the labeling of long-lived cells such as lymphocytes. Laboratory studies have demonstrated impaired cell function at high concentrations of radioactivity. Some workers have expressed concern about long-term changes in cells that recirculate. Others cite precedents of other long-term uses of isotopes, therapeutically, without detrimental effects. These concerns continue to be investigated. Finally, an area of much interest in the use of indium-111 is the labeling of granulocytes. This technique has been useful diagnostically, to localize infections. The major value in patients with malignancy, primarily with hematologic malignancies, is to evaluate the potential benefit of granulocyte transfusions. Many of these patients develop prolonged granulocytopenia and become infected, and granulocyte transfusions may become a therapeutic consideration.(ABSTRACT TRUNCATED AT 400 WORDS)
放射性同位素用于细胞标记一直是血液学实验室研究的主要工具。铬-51标记血液细胞和淋巴细胞多年来一直用于研究这些细胞在脾脏和其他部位的迁移和滞留。淋巴细胞从血液大量再循环至淋巴组织然后再回到血液的过程已得到充分描述。最近,放射性同位素细胞标记的新方法在恶性疾病各个方面的研究以及此类患者的临床护理中变得突出。诸如铟-111等同位素可用标准扫描技术进行可视化,从而发现有关正常和恶性细胞迁移的更多信息。已在动物和人类中用铟-111进行了体内研究,包括比较异常细胞(恶性)和淋巴细胞向异常淋巴结的迁移。对动物体内癌细胞、正常淋巴细胞和恶性淋巴细胞迁移的评估和比较显示出明显不同的分布模式,这可能与转移机制的研究有关。人体体内研究也评估了慢性淋巴细胞白血病和高分化淋巴瘤患者淋巴细胞的迁移模式,显示出这两种相似疾病极性之间非常不同的迁移行为。这些类型的研究虽然最初是现象学的,但可能为更好地理解这些疾病提供基础。对于使用铟-111等同位素标记淋巴细胞等长寿命细胞存在担忧。实验室研究表明,在高放射性浓度下细胞功能受损。一些研究人员对再循环细胞的长期变化表示担忧。其他人则引用了同位素其他长期治疗用途的先例,认为没有有害影响。这些担忧仍在研究中。最后,铟-111使用中一个备受关注的领域是粒细胞标记。该技术在诊断上有助于定位感染。对于恶性肿瘤患者,主要是血液系统恶性肿瘤患者,其主要价值在于评估粒细胞输注的潜在益处。许多此类患者会出现长期粒细胞减少并发生感染,粒细胞输注可能成为一种治疗选择。(摘要截选至400字)